Home Companies Catalysts Deep Dives
Trajenta linagliptin APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Launch2011-05-02
US LOE2027-01-01
Peak Sales Est$2000M
Formulations[{"id":"trajenta-oral","doses":"5mg tablets","route":"Oral","setting":"PATIENT_SELF","frequency":"On
Companies
BI (CO_DEVELOPER)50%
LLY (CO_DEVELOPER)50%
Mechanism: DPP-4 inhibitor
Expert: Dipeptidyl peptidase-4 inhibitor that prevents degradation of endogenous GLP-1 and GIP, enhancing incretin-mediated glucose-dependent insulin secretion and glucagon suppression.
Everyday: Helps the body keep more of a natural hormone that lowers blood sugar after meals. A daily pill for type 2 diabetes.
Targets: ["DPP-4"]
Revenue History
PeriodRevenue ($M)
2023$1,892M
2024$1,756M
Q1 2025$410M
Programs (1)
IndicationStageKey StudyRegional Status
T2DAPPROVEDCARMELINA[{"stage":"APPROVED","region":"US","approval_date":"2011-05-02"},{"stage":"APPRO
Notes
DPP-4 inhibitor with no renal dose adjustment needed. Mature product.
Data from Supabase · Updated 2026-03-24